China (Mainland)
Premiumsupplier
- Product Details
Keywords
- 231277-92-2
- Lapatinib seller in China
- Sell high quality 231277-92-2 produced in China factory
Quick Details
- ProName: Lapatinib
- CasNo: 231277-92-2
- Molecular Formula: C29H26ClFN4O4S
- Appearance: white powder
- Application: Used for research and industrial manuf...
- DeliveryTime: Within 3-7 days after receipt of your ...
- PackAge: As customer request
- Port: QINGDAO CHINA
- ProductionCapacity: 100 Metric Ton/Day
- Purity: 98%min
- Storage: Store in a cool,dry place and keep awa...
- Transportation: Common products:Sea/Air/Courier Dange...
- LimitNum: 100 Metric Ton
Superiority
Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.
Details
Details
Specifications
Lapatinib
1.CAS:231277-92-2
2.Purity:99%
3.White powder
4.for breast cancer and other solid tumours
Lapatinib
CAS-No.:231277-92-2
Molecular Formula:C29H26ClFN4O4S
Molecular Weight:581.0575432
Purity:99%
Appearance:White to yellow powder
Lapatinib is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2)
Specifications
Lapatinib
1.CAS:231277-92-2
2.Purity:99%
3.White powder
4.for breast cancer and other solid tumours
Lapatinib
CAS-No.:231277-92-2
Molecular Formula:C29H26ClFN4O4S
Molecular Weight:581.0575432
Purity:99%
Appearance:White to yellow powder
Lapatinib is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2)
